The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study
| Author | Maissa El Raziky | en |
| Author | Waleed Fouad Fathalah | en |
| Author | Wafaa Ahmed El-akel | en |
| Author | Ahmed Salama | en |
| Author | Gamal Esmat | en |
| Author | Mahassen Mabrouk | en |
| Author | Rabab Mamoun Salama | en |
| Author | Hany Mahmoud Khatab | en |
| Issued Date | 2013-05-28 | en |
| Abstract | Background: Egypt has one of the highest (16-8%) prevalence rates of HCV infection in the world. Approximately 90% of Egyptian HCV isolates belong to a single subtype (4a), which responds less successfully to interferon therapy than other subtypes. Studies comparing the efficacy and safety of PEGIFN alfa-2a and PEGIFN alfa-2b in treatment-naive HCV-infected patients have shown conflicting results. Objectives: assessing the effects of Peginterferon alpha-2a versus Peginterferon alpha-2b on the sustained virological response in naive chronic HCV genotype-4 Egyptian patients. Patients and Methods: this retrospective study cohort consists of 3718 chronic HCV patients admitted to a large, Egyptian medical center. 1985 patients had been treated with PEG-IFN alfa-2a plus RBV and 1733 patients with PEG-IFN alfa-2b plus RBV between years 2007-2011. Efficacy outcomes were sustained virologic response (SVR) and treatment discontinuation rates due to serious adverse effects. Results: The ETR & SVR in patients treated with PEGIFN alfa-2a was 64.1% and 59.6% as compared to treatment with PEGIFN alfa-2b where these parameters were 58.2% and 53.9% respectively (P < 0.05). Treatment discontinuation rates, were similar in the two types of PEGIFN [0.66 (0.37-1.16); P = 0.15]. Significant dose reduction was evident with peginterferon alfa-2b (35.3%) than peginterferon alpha-2a (27.3 %) (P < 0.01). Patients with lower base line AFP and ALT were most likely to achieve SVR using INF alpha 2-a. Conclusions: Peginterferon alpha-2a has a higher efficacy regarding ETR and SVR as compared to Peginterferon alfa-2b in treatment of naive chronic HCV genotype-4 patients. | en |
| DOI | https://doi.org/10.5812/hepatmon.10069 | en |
| Keyword | Chronic Hepatitis C | en |
| Keyword | Peginterferon-Alpha- 2a | en |
| Keyword | Peginterferon-Alpha- 2b | en |
| Publisher | Brieflands | en |
| Title | The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 70462-pdf.pdf
- Size:
- 242.66 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF